







FAX Completed Form To 1.833.404.2392

Pharmacy Help Desk 1.800.460.8988

Prescriber Help Desk 1.833.587.2012

## Request for Prior Authorization Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB				
Patient address						
Duras didan NIDI	Due couile ou moure	Dhana				
Provider NPI	Prescriber name	Phone				
Prescriber address		Fax				
Pharmacy name	Address	Phone				
,						
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.						
Pharmacy NPI	Pharmacy fax NDC					
	1					

Prior authorization is required for oral gonadotropin-releasing hormone (GnRH) antagonists. Payment for non-preferred oral GnRH antagonists may be considered only for cases in which there is documentation of a previous trial and therapy failure with the preferred agent. Payment will be considered for patients when the following is met:

- 1) Pregnancy has been ruled out; and
- 2) Patient does not have osteoporosis; and
- 3) Request adheres to all FDA approved labeling for requested drug, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
- 4) Requests for elagolix (Orilissa) will be considered under the following conditions:
  - a. Patient has a diagnosis of moderate to severe pain associated with endometriosis; and
  - b. Patient has documentation of a previous trial and therapy failure with at least one preferred oral NSAID and at least one preferred 3-month course of a continuous hormonal contraceptive taken concurrently; and
  - c. Patient has documentation of a previous trial and therapy failure with a preferred GnRH agonist.
  - d. Initial requests will be considered for 3 months. Additional requests will be considered upon documentation of improvement of symptoms.
  - e. Requests will be considered for a maximum of 24 months for the 150mg dose and 6 months for the 200mg dose; or
- 5) Requests for elagolix, estradiol, and norethindrone acetate; elagolix (Oriahnn) or relugolix, estradiol, norethindrone acetate (Myfembree) will be considered under the following conditions:
  - a. Patient is premenopausal; and
  - b. Patient has a diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids); and
  - c. Patient has documentation of a previous trial and therapy failure with at least one preferred 3-month course of a continuous hormonal contraceptive; and
  - d. Patient has documentation of a previous trial and therapy failure with tranexamic acid.
  - e. Initial requests will be considered for 6 months. Additional requests will be considered upon documentation of improvement in symptoms.
  - f. Requests will be considered for a maximum of 24 months of treatment.









FAX Completed Form To 1.833.404.2392

Pharmacy Help Desk 1.800.460.8988

Prescriber Help Desk 1.833.587.2012

## Request for Prior Authorization Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Preferred	Non-Preferred				
☐ Oriahnn	☐ Myfembree	Oriliss	a		
Strength	Dosage Instru	uctions	Quantity	Days Supply	
Diagnosis:					
☐ Initial Requests:					
Has pregnancy been ru	ıled out?	es 🗌 No D	ate of pregnancy test:		
Does patient have oste	oporosis?	es 🗌 No			
Does patient have seve	ere hepatic impairmen	t? 🗌 Yes 🗀	] No		
Is patient taking a strong or gemfibrozil)?  Yes	rganic anion transport No	ing polypeptid	e (OATP) 1B1 inhibitor	e.g., cyclosporine and	t
Treatment Failures:					
Preferred Oral NSAID Tria	al.				
Name/dose:			Trial dates:		
Failure reason/medical con					
Preferred Continuous Ho	rmonal Contraceptiv	e Trial:			
Name/dose:					
Failure reason/medical con	traindication:				
Duefermed Curple Association	Trial				
Preferred GnRH Agonist Name/dose:					
1 141110/4030			Trial dates:		

Rev. 1/22 Page 2 of 3









FAX Completed Form To 1.833.404.2392

Pharmacy Help Desk 1.800.460.8988

Prescriber Help Desk 1.833.587.2012

## Request for Prior Authorization Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Oriahnn & Myfembree			
Is patient premenopausal?	☐ Yes ☐ No		
Treatment Failures:			
Preferred Continuous Hormonal C	Contraceptive Trial:		
Name/dose:		Trial dates:	_
Failure reason/medical contraindical	tion:		
Tranexamic Acid Trial:			
Name/dose:		Trial dates:	
Failure reason/medical contraindical			
Reason for use of Non-Preferred	drug requiring prior appro	oval:	
Renewal Requests:			
Provide documentation of improvem	nent in symptoms:		
Treatment start date:			
Attach lab results and other docu	mentation as necessary.		
Prescriber signature (Must match prescr	iber listed above.)	Date of submission	

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

Rev. 1/22 Page 3 of 3